Exomind (rTMS)

Exomind vs Antidepressants: Comparing Two Paths to Recovery

Medication and Exomind (rTMS) work through completely different mechanisms. Here's how they compare on how they work, what to expect, and who each suits best.

2 min read

Written by

Dr. Muhammad Shoaib Zafar

Consultant Psychiatrist and Addiction Specialist

MBBS — University of Health Sciences (UHS); MD Psychiatry — King Edward Medical University (KEMU); MPH — Institute of Public Health (IPH); UNODC Certified Addiction Specialist; International Certification of Addiction Professionals (ICAP-P); Formal training/fellowship in Child & Adolescent Psychiatry — King Edward Medical University, Lahore

View profile
Published:
Exomind vs Antidepressants: Comparing Two Paths to Recovery

When first-line antidepressant treatment hasn't produced enough improvement, the natural next question is: try a different medication, or consider something like Exomind (rTMS) instead? They work in fundamentally different ways, and understanding that difference helps make sense of why one might be recommended over the other in a given case.

Antidepressants work systemically. Most classes work by adjusting neurotransmitter levels or activity throughout the brain and body, which is why they can take several weeks to show effect and why side effects — weight changes, sexual side effects, sleep changes, and others depending on the specific medication — tend to be systemic rather than localised.

Exomind works locally, through magnetic stimulation. rTMS delivers targeted magnetic pulses to specific brain regions involved in mood regulation, without circulating through the bloodstream the way a pill does. This generally means a different side-effect profile — most commonly scalp discomfort or headache during treatment — without the systemic side effects associated with many medications.

Time commitment differs significantly. Medication is typically a daily pill once a stable dose is found. Exomind requires attending sessions at a clinic, often multiple times per week over several weeks for a full course — a bigger time commitment upfront, but without an ongoing daily dosing routine afterward.

They're often considered at different treatment stages. Antidepressants are generally first-line treatment. Exomind is typically considered after standard treatment — medication combined with therapy — hasn't produced adequate improvement, making it a second-line rather than a replacement-first option in most cases.

They can also be used together. It isn't strictly an either/or choice — some patients continue medication while undergoing an Exomind course, and the two approaches aren't mutually exclusive within a broader treatment plan.

Neither is a guaranteed fix. As with any psychiatric treatment, individual response varies, and realistic expectations are set at the start of treatment rather than assumed.

The right path depends on your specific history — what's been tried already, how you've responded, and what your priorities are (daily pill vs. clinic visits, systemic side effects vs. localised ones). That's exactly what a treatment-planning consultation is for.

About the author

Dr. Muhammad Shoaib Zafar

Consultant Psychiatrist and Addiction Specialist

MBBS — University of Health Sciences (UHS); MD Psychiatry — King Edward Medical University (KEMU); MPH — Institute of Public Health (IPH); UNODC Certified Addiction Specialist; International Certification of Addiction Professionals (ICAP-P); Formal training/fellowship in Child & Adolescent Psychiatry — King Edward Medical University, Lahore

King Edward Medical University (KEMU) & Mayo Hospital, Lahore

clinical interests

Adult Psychiatry; Addiction Psychiatry & Rehabilitation; Child & Adolescent Psychiatry; Psychotherapy & Psychological Interventions; Psychiatric Assessment & Consultation

training

Formal training/fellowship in Child & Adolescent Psychiatry, King Edward Medical University, Lahore

memberships

Pakistan Medical & Dental Council (PMDC); Pakistan Psychiatric Society (PPS); International Certification of Addiction Professionals (ICAP)

Dr. Muhammad Shoaib Zafar, MBBS, MD (Psychiatry) Assistant Professor of Psychiatry, King Edward Medical University (KEMU), Lahore

Tags

ExomindrTMSantidepressantstreatment-resistant depression